A powerful former Chairman of the House Energy and Commerce Committee, Dingell has not been only a major player in the health care reform fight, but also a vigorous prober of FDA, launching investigations with lasting effects on the device center. The longest-serving member of the House announced his plans to retire at the end of this congressional term.
Rep. John Dingell, D-Mich., who announced his retirement from the House Feb. 24, played a major role in the evolution of health care policy in the past half-century, including active oversight of FDA medical device policies.
A powerful former Chairman of the House Energy and Commerce Committee, Dingell is the longest-serving member of the House with 59 years of service. He has been re-elected repeatedly after...
The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.
Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
